

CITATION REPORT

List of articles citing

Intestinal microbiome analysis revealed dysbiosis in sickle cell disease

DOI: 10.1002/ajh.25019

American Journal of Hematology, 2018, 93, E91-E93.

Source: <https://exaly.com/paper-pdf/69132076/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
47	Invasive non-typhoidal Salmonella in sickle cell disease in Africa: is increased gut permeability the missing link?. <i>Journal of Translational Medicine</i> , 2018 , 16, 239	8.5	10
46	Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. <i>Onc Immunology</i> , 2018 , 7, e1507670	7.2	72
45	Emerging disease-modifying therapies for sickle cell disease. <i>Haematologica</i> , 2019 , 104, 1710-1719	6.6	32
44	Rifaximin for sickle cell disease. <i>American Journal of Hematology</i> , 2019 , 94, E325-E328	7.1	13
43	Depletion of Intestinal Microbiome Partially Rescues Bone Loss in Sickle Cell Disease Male Mice. <i>Scientific Reports</i> , 2019 , 9, 8659	4.9	12
42	Intestinal injury and gut permeability in sickle cell disease. <i>Journal of Translational Medicine</i> , 2019 , 17, 183	8.5	22
41	Elevated urinary 3-indoxyl sulfate in sickle cell disease. <i>American Journal of Hematology</i> , 2019 , 94, E162-E164	7.1	5
40	Low Incidence of Hospital-Onset Infection in Sickle Cell Disease. <i>New England Journal of Medicine</i> , 2019 , 380, 887-888	59.2	9
39	Intestinal pathophysiological and microbial changes in sickle cell disease: Potential targets for therapeutic intervention. <i>British Journal of Haematology</i> , 2020 , 188, 488-493	4.5	9
38	Rifaximin on intestinally-related pathologic changes in sickle cell disease. <i>American Journal of Hematology</i> , 2020 , 95, E83-E86	7.1	8
37	Differences in Gut Microbiome in Hospitalized Immunocompetent vs. Immunocompromised Children, Including Those With Sickle Cell Disease. <i>Frontiers in Pediatrics</i> , 2020 , 8, 583446	3.4	6
36	Convergence of Inflammatory Pathways in Allergic Asthma and Sickle Cell Disease. <i>Frontiers in Immunology</i> , 2019 , 10, 3058	8.4	3
35	Clinicopathologic consequences following discontinuation of rifaximin in patients with sickle cell disease. <i>American Journal of Hematology</i> , 2020 , 95, E151-E153	7.1	2
34	High incidence of healthcare facility-acquired Clostridium difficile infections in chronic opioid users. <i>Journal of Internal Medicine</i> , 2021 , 289, 129-130	10.8	2
33	A contemporary review of Clostridioides difficile infections in patients with haematologic diseases. <i>Journal of Internal Medicine</i> , 2021 , 289, 293-308	10.8	3
32	Sickle cell disease is a global prototype for integrative research and healthcare. <i>Genetics & Genomics Next</i> , 2021 , 2, e10037	1.2	1
31	Drug Repurposing Patent Applications October-December 2020. <i>Assay and Drug Development Technologies</i> , 2021 , 19, 209-214	2.1	

30 Obesity and diabetes mellitus in patients with sickle cell disease. *Annals of Hematology*, **2021**, 100, 2203-2205 1

29 Antibiotics to modify sickle cell disease vaso-occlusive crisis?. *Blood Reviews*, **2021**, 50, 100867 11.1 1

28 The gut microbiome in sickle cell disease: Characterization and potential implications. *PLoS ONE*, **2021**, 16, e0255956 3.7 2

27 Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events. *Journal of Translational Medicine*, **2021**, 19, 397 8.5 5

26 Respiratory and Neurological Disease across Different Ethnic Groups Is Influenced by the Microbiome. *Microorganisms*, **2021**, 9, 4.9 0

25 Very low incidence of Clostridioides difficile infection in pediatric sickle cell disease patients. *Haematologica*, **2020**, 106, 1489-1490 6.6 1

24 Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice.. *Cancers*, **2022**, 14, 6.6 0

23 Human microbiota research in Africa: a systematic review reveals gaps and priorities for future research.. *Microbiome*, **2021**, 9, 241 16.6 1

22 Genes modulating intestinal permeability and microbial community are dysregulated in sickle cell disease.. *Annals of Hematology*, **2022**, 101, 1009 3 0

21 Image_1.JPEG. **2020**,

20 Image_2.JPEG. **2020**,

19 Image_3.JPEG. **2020**,

18 Image_4.JPEG. **2020**,

17 Image_5.JPEG. **2020**,

16 Image_6.JPEG. **2020**,

15 Image_7.JPEG. **2020**,

14 Table_1.docx. **2020**,

13 L-glutamine for sickle cell disease: more than reducing redox.. *Annals of Hematology*, **2022**, 1 3 0

12	Recent advances in sickle and niche research - Tribute to Dr. Paul S Frenette - <i>Stem Cell Reports</i> , 2022 , 17, 1509-1535	8	o
11	Emerging drugs for the treatment of sickle cell disease: a review of phase II/III trials. 2022 , 27, 211-224		o
10	How Hydroxyurea Alters the Gut Microbiome: A Longitudinal Study Involving Angolan Children with Sickle Cell Anemia. 2022 , 23, 9061		o
9	Microbial gut evaluation in an angolan paediatric population with sickle cell disease.		o
8	Neutrophils as drivers of vascular injury in sickle cell disease.		1
7	Bone loss is ameliorated by fecal microbiota transplantation through SCFA/GPR41/IGF1 pathway in sickle cell disease mice. 2022 , 12,		1
6	Intestinal barrier dysfunction in murine sickle cell disease is associated with small intestine neutrophilic inflammation, oxidative stress, and dysbiosis.		o
5	Glutamine and sickle cell disease in Brazilian scenario. 2023 , 7, 43-51		o
4	Intestinal barrier functions in hematologic and oncologic diseases. 2023 , 21,		o
3	The effect of hydroxyurea response on gut microbiota of beta-thalassemia major patients.		o
2	Effects of GBT1118 , a voxelotor analog, on intestinal pathophysiology in sickle cell disease.		o
1	The relationship between nutrition, gut dysbiosis, and pediatric sickle cell pain outcomes: A pilot study.		o